XVIVO — Xvivo Perfusion AB Share Price
0.000.00%
Last trade - 00:00- SEK15.43bn
- SEK15.01bn
- SEK597.54m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 79.99 | ||
| PEG Ratio (f) | 2.76 | ||
| EPS Growth (f) | 40.73% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.41 | ||
| Price to Tang. Book | 19.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.56 | ||
| EV to EBITDA | 116.81 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.67% | ||
| Return on Equity | 10.18% | ||
| Operating Margin | 7.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 220.84 | 179.86 | 258.39 | 415.29 | 597.54 | 821.4 | 1,109.84 | 26.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -61.37 | n/a | n/a | +201.33 | +147.76 | +106.28 | +40.73 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Directors
- Gosta Johannesson CHM (62)
- Dag Andersson PRE (60)
- Christoffer Rosenblad DCE (46)
- Kristoffer Nordstrom CFO (63)
- Katrin Gisselfalt OTH (52)
- Johan Holmstroem OTH (51)
- Charlotte Walldal OTH (54)
- Andreas Wallinder OTH (44)
- Lars Henriksson IND (66)
- Lena Hoglund IND (61)
- Yvonne Martensson IND (68)
- Folke Nilsson IND (71)
- Camilla Oberg IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- December 17th, 1998
- Public Since
- October 8th, 2012
- No. of Shareholders
- 8,826
- No. of Employees
- 161
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 31,499,470
- Address
- Massans gata 10, GOETEBORG, 412 51
- Web
- https://www.xvivoperfusion.com/
- Phone
- +46 317882150
- Contact
- Kristoffer Nordstroem
- Auditors
- KPMG AB
Upcoming Events for XVIVO
Q4 2024 Xvivo Perfusion AB Earnings Call
Q1 2025 Xvivo Perfusion AB Earnings Release
Xvivo Perfusion AB Annual Shareholders Meeting
Q2 2025 Xvivo Perfusion AB Earnings Release
Similar to XVIVO
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Xvivo Perfusion AB share price?
As of Today at 23:10 UTC, shares in Xvivo Perfusion AB are trading at SEK490.00. This share price information is delayed by 15 minutes.
How has the Xvivo Perfusion AB share price performed this year?
Shares in Xvivo Perfusion AB last closed at SEK490.00 and the price had moved by +49.39% over the past 365 days. In terms of relative price strength the Xvivo Perfusion AB share price has outperformed the FTSE Global All Cap Index by +38.01% over the past year.
What are the analyst and broker recommendations for Xvivo Perfusion AB?
The overall consensus recommendation for Xvivo Perfusion AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Xvivo Perfusion AB dividend yield?
Xvivo Perfusion AB does not currently pay a dividend.
Does Xvivo Perfusion AB pay a dividend?
Xvivo Perfusion AB does not currently pay a dividend.
When does Xvivo Perfusion AB next pay dividends?
Xvivo Perfusion AB does not currently pay a dividend.
How do I buy Xvivo Perfusion AB shares?
To buy shares in Xvivo Perfusion AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xvivo Perfusion AB?
As of the previous close price of SEK490.00, shares in Xvivo Perfusion AB had a market capitalisation of SEK15.43bn.
Where are Xvivo Perfusion AB shares listed?
Here are the trading details for Xvivo Perfusion AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: XVIVO
What kind of share is Xvivo Perfusion AB?
Based on an overall assessment of its quality, value and momentum Xvivo Perfusion AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xvivo Perfusion AB share price forecast for 2025?
The analyst consensus target price for shares in Xvivo Perfusion AB is SEK533.80. That is 8.94% above the last closing price of SEK490.00.
Analysts covering Xvivo Perfusion AB currently have a consensus Earnings Per Share (EPS) forecast of SEK4.35 for the next financial year.
Find out moreWhat is the trend in the Xvivo Perfusion AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xvivo Perfusion AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -3.91%.
As of the last closing price of SEK490.00, shares in Xvivo Perfusion AB were trading +9.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xvivo Perfusion AB PE Ratio?
The Xvivo Perfusion AB PE ratio based on its reported earnings over the past 12 months is 79.99. The shares last closed at SEK490.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xvivo Perfusion AB?
Xvivo Perfusion AB's management team is headed by:
- Gosta Johannesson - CHM
- Dag Andersson - PRE
- Christoffer Rosenblad - DCE
- Kristoffer Nordstrom - CFO
- Katrin Gisselfalt - OTH
- Johan Holmstroem - OTH
- Charlotte Walldal - OTH
- Andreas Wallinder - OTH
- Lars Henriksson - IND
- Lena Hoglund - IND
- Yvonne Martensson - IND
- Folke Nilsson - IND
- Camilla Oberg - IND